Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

Open to people ages 18 years and up

• >= 18 years of age
• Preoperative imaging characteristics consistent with brain glioblastoma (magnetic resonance imaging [MRI] brain)
• Patients who are undergoing neurosurgical resection for treatment of glioblastoma
• Ability to understand and willingness to sign an informed consent form
• Ability to adhere to the study visit schedule and other protocol requirements

• Prior treatment for glioblastoma

• Glioblastoma size less than 5 cm³

• Known allergy against amide type of local anesthetics
• History of severe cardiac failure (determined by clinical history of less the 3 Metabolic Equivalent of Tasks [METs])
• 2nd or 3rd degree heart block (exception: patients with pacemaker)
• Concurrent treatment with class I or III antiarrhythmics (phenytoin, procainamide, propranolol, quinidine) or amiodarone use =< 3 months
• History of Wolff-Parkinson-White syndrome, Stokes Adams syndrome, or active dysrhythmia
• History of bradycardia
• Prior clinical history of severe hepatic impairment or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 1.55 times of upper normal limit
• Prior clinical history of severe renal impairment or estimated glomerular filtration rate (EGFR) < 30ml/min
• Uncontrolled seizure disorder
• Acute porphyria
• Patients requiring an awake fiberoptic intubation due to administration of additional lidocaine
• Pregnant or lactating women
• Any condition that would prohibit the understanding or rendering of informed consent
• Any medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would prevent the subject from participating and adhering to study related procedures
• Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial